Provider: Sadif Analytics Prime
Integragen SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
IntegraGen shares rise sharply on news of collaboration deal with Pfizer-Reuters
IntegraGen SA:Shares rise sharply following news of collaboration agreement with Pfizer-Reuters.Agreement with Pfizer to evaluate IntegraGen's hepatocellular carcinoma molecular signature.
Latest Developments for Integragen SA
- IntegraGen announces MIR-31-3P biomarker trial results
- IntegraGen announces study showing relationship between survival time without progression and expression of microARN hsa-miR-31-3p in patients treated with anti-EGFR therapy
- IntegraGen gives FY 2014 outlook
- IntegraGen SA sequences more than 100 breast cancer metastases
Latest Key Developments in Biotechnology
- Share this
- Digg this